title: para-Nitrophenyl sulfate activation of human sulfotransferase 1A1 is consistent with intercepting the E[middle dot]PAP complex and reformation of E[middle dot]PAPS.
abstract: Cytosolic sulfotransferase (SULT)-catalyzed sulfation regulates biological activities of various biosignaling molecules and metabolizes hydroxyl-containing drugs and xenobiotics. The universal sulfuryl group donor for SULT-catalyzed sulfation is adenosine 3'-phosphate 5'-phosphosulfate (PAPS), whereas the reaction products are a sulfated product and adenosine 3',5'-diphosphate (PAP). Although SULT-catalyzed kinetic mechanisms have been studied since the 1980s, they remain unclear. Human SULT1A1 is an important phase II drug-metabolizing enzyme. Previously, isotope exchange at equilibrium indicated steady-state ordered mechanism with PAPS and PAP binding to the free SULT1A1 (Tyapochkin, E., Cook, P. F., and Chen, G. (2008) Biochemistry 47, 11894-11899). On the basis of activation of SULT1A1 by para-nitrophenyl sulfate (pNPS), an ordered bypass mechanism has been proposed where pNPS sulfates PAP prior to its release from the E.PAP complex regenerating E.PAPS. Data are consistent with uncompetitive substrate inhibition by naphthol as a result of formation of the E.PAP.naphthol dead-end complex; formation of the complex is corroborated by naphthol/PAP double inhibition experiments. pNPS activation data demonstrate an apparent ping-pong behavior with pNPS adding to E.PAP, and competitive inhibition by naphthol consistent with formation of the E.PAP.naphthol complex. Exchange against forward reaction flux (PAPS plus naphthol) beginning with [35S]PAPS and generating [35S]naphthyl sulfate is also consistent with pNPS intercepting the E.PAP complex. Overall, data are consistent with the proposed ordered bypass mechanism.
authors.affiliation: Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma 74078, USA.
authors.forename: Eduard
authors.initials: E
authors.lastname: Tyapochkin
authors.forename: Paul F
authors.initials: PF
authors.lastname: Cook
authors.forename: Guangping
authors.initials: G
authors.lastname: Chen
mesh_terms: D000244:Adenosine Diphosphate / Q000737:chemistry*; D015239:Arylsulfotransferase / Q000737:chemistry*; D004789:Enzyme Activation; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D009578:Nitrobenzenes / Q000737:chemistry*; D010724:Phosphoadenosine Phosphosulfate / Q000737:chemistry*
chemical_list: D009578:Nitrobenzenes; C023379:4-nitrophenyl sulfate; D010724:Phosphoadenosine Phosphosulfate; D000244:Adenosine Diphosphate; C010840:adenosine 3'-phosphate-5'-phosphate; D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human
references.citation: Nat Struct Biol. 1997 Nov;4(11):904-8
references.pmid: 9360604
references.citation: Biochemistry. 1975 Jul 15;14(14):3220-4
references.pmid: 1148201
references.citation: Angew Chem Int Ed Engl. 2004 Jul 5;43(27):3526-48
references.pmid: 15293241
references.citation: Anal Biochem. 1998 Nov 1;264(1):111-7
references.pmid: 9784194
references.citation: Nat Struct Biol. 2001 May;8(5):447-51
references.pmid: 11323722
references.citation: Pharmacogenomics J. 2002;2(5):297-308
references.pmid: 12439736
references.citation: Toxicol Lett. 2000 Mar 15;112-113:341-8
references.pmid: 10720750
references.citation: J Biol Chem. 1981 Nov 10;256(21):11123-7
references.pmid: 6945304
references.citation: J Biol Chem. 2004 Apr 30;279(18):18799-805
references.pmid: 14871892
references.citation: Drug Metab Dispos. 2001 Apr;29(4 Pt 2):522-8
references.pmid: 11259344
references.citation: Int J Clin Pharmacol Ther. 2004 Sep;42(9):488-95
references.pmid: 15487807
references.citation: Protein Sci. 2005 Jan;14(1):176-82
references.pmid: 15608121
references.citation: J Steroid Biochem Mol Biol. 1995 Jun;52(6):529-39
references.pmid: 7779757
references.citation: Curr Drug Metab. 2005 Aug;6(4):299-307
references.pmid: 16101570
references.citation: Acta Crystallogr D Biol Crystallogr. 2000 Dec;56(Pt 12):1641-3
references.pmid: 11092933
references.citation: Biochem J. 2002 May 15;364(Pt 1):165-71
references.pmid: 11988089
references.citation: Chem Biol Interact. 2000 Dec 1;129(1-2):141-70
references.pmid: 11154739
references.citation: Protein Sci. 1999 Oct;8(10):2151-7
references.pmid: 10548061
references.citation: FASEB J. 1997 Mar;11(4):206-16
references.pmid: 9068609
references.citation: Biochim Biophys Acta. 2003 May 30;1648(1-2):134-9
references.pmid: 12758156
references.citation: Drug Metab Dispos. 2000 Sep;28(9):1063-8
references.pmid: 10950850
references.citation: J Biol Chem. 2003 Feb 28;278(9):7655-62
references.pmid: 12471039
references.citation: Xenobiotica. 2005 Dec;35(12):1101-19
references.pmid: 16418064
references.citation: Drug Metab Dispos. 1995 Aug;23(8):840-5
references.pmid: 7493551
references.citation: Drug Metab Rev. 2001 Aug-Nov;33(3-4):369-95
references.pmid: 11768773
references.citation: Arch Biochem Biophys. 1964 Jul 20;106:243-51
references.pmid: 14217165
references.citation: Environ Health Perspect. 2003 Jun;111(7):884-8
references.pmid: 12782487
references.citation: Biochemistry. 2000 Dec 26;39(51):16000-7
references.pmid: 11123927
references.citation: J Biol Chem. 1974 May 10;249(9):2928-31
references.pmid: 4151309
references.citation: Biochemistry. 1986 Jan 14;25(1):227-36
references.pmid: 3513825
references.citation: Curr Drug Metab. 2006 Jan;7(1):83-104
references.pmid: 16454694
references.citation: Toxicol Sci. 2006 Mar;90(1):5-22
references.pmid: 16322073
references.citation: Biochemistry. 2008 Nov 11;47(45):11894-9
references.pmid: 18928301
references.citation: Methods Enzymol. 1979;63:500-13
references.pmid: 502868